Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bonneterre

Showing results (151-160 of 194) with videos related to

Pageof 20
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2005
Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trialsM Namer, P Fargeot, H Roché, et al.
The Journal of Steroid Biochemistry and Molecular Biology|September 1, 1992
Basic fibroblast growth factor (bFGF): mitogenic activity and binding sites in human breast cancerJ P Peyrat, J Bonneterre, H Hondermarck, et al.
European Journal of Cancer & Clinical Oncology|October 1, 1985
Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/dayJ Bonneterre, H Coppens, L Mauriac, et al.
Cancer|December 18, 2001
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinomaJ Bonneterre, A Buzdar, J M Nabholtz, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2000
Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal womenI Vergote, J Bonneterre, B Thürlimann, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancerJ Bonneterre, P Kerbrat, P Fargeot, et al.
Acta Clinica Belgica. Supplementum|January 1, 1986
[Aminoglutethimide in advanced breast cancer. Multicenter trial comparing 500 mg and 1000 mg per day]J Bonneterre, H Coppens, L Mauriac, et al.
Therapie|September 1, 1992
[Multicenter prospective study of cardiac accidents during treatments with 5-FU]F Sorbette, I Simon, J Bonneterre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: an interim analysis of a phase II multicenter studyJ P Guastalla, C Lhommé, J Dauplat, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study GroupM F Avril, J Bonneterre, M Delaunay, et al.
Pageof 20

Showing results (151-160 of 194) with videos related to

Sort By:
Pageof 20
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2005
Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trialsM Namer, P Fargeot, H Roché, et al.
The Journal of Steroid Biochemistry and Molecular Biology|September 1, 1992
Basic fibroblast growth factor (bFGF): mitogenic activity and binding sites in human breast cancerJ P Peyrat, J Bonneterre, H Hondermarck, et al.
European Journal of Cancer & Clinical Oncology|October 1, 1985
Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/dayJ Bonneterre, H Coppens, L Mauriac, et al.
Cancer|December 18, 2001
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinomaJ Bonneterre, A Buzdar, J M Nabholtz, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2000
Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal womenI Vergote, J Bonneterre, B Thürlimann, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancerJ Bonneterre, P Kerbrat, P Fargeot, et al.
Acta Clinica Belgica. Supplementum|January 1, 1986
[Aminoglutethimide in advanced breast cancer. Multicenter trial comparing 500 mg and 1000 mg per day]J Bonneterre, H Coppens, L Mauriac, et al.
Therapie|September 1, 1992
[Multicenter prospective study of cardiac accidents during treatments with 5-FU]F Sorbette, I Simon, J Bonneterre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: an interim analysis of a phase II multicenter studyJ P Guastalla, C Lhommé, J Dauplat, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study GroupM F Avril, J Bonneterre, M Delaunay, et al.
Pageof 20